The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC).
 
Ferdinandos Skoulidis
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; BergenBio; Bridgebio; Calithera Biosciences; Guardant Health; Hookipa Pharma; Merck; Novartis; Novocure; Revolution Medicines; Tango Therapeutics
Research Funding - Amgen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Revolution Medicines (Inst)
Other Relationship - American Association for Cancer Research; Amgen; AstraZeneca; Curio LLC; DAVA Oncology; ESMO; Genentech/Roche; IASLC; Ideology Health; Intellisphere; Japanese Lung Cancer; McGill Universite de Montreal; Medscape; Merck; MI and T; MJH Life Sciences; Novartis; PER; Revolution Health Care; RV Mais Promocao Events LTDS; Tango Therapeutics
 
Kristof Cuppens
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen; MSD; Roche/Genentech
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst)
Expert Testimony - AstraZeneca; MSD
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Roche/Genentech
 
Adrian G. Sacher
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Merck
 
Vamsidhar Velcheti
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; ChongKeunDang Healthcare; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ABION; ST Cube
 
Mark T. Lin
Employment - Genentech
 
Tharu M. Fernando
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Genentech
 
Shuai Li
Employment - Genentech
 
Denise Bradley
Employment - Roche
 
Martina Zarak Crnkovic
Employment - Roche
 
Michael Mathisen
Employment - Roche/Genentech